MD Virologist,

Can you post me to an article describing viral entry inhibition. I did not see anything about that in the trial description or the biospace interview with the CEO

I also have not been able to find any support for the clam in that it blocks RANTES.

“ Oh I forgot to mention it is also a RANTES inhibitor. “

https://investorshangout.com/post/view?id=5854352


I remain cautiously optimistic about its role in ARDS, but noted a very significant list of exclusionary trial criteria.

Pregnancy (pregnant women may apply for open label treatment under compassionate care IND
Age <18 years
Mechanical ventilation for more than 7 days in primary cohort. Mechanical ventilation>21 days in the exploratory cohort
Mean Arterial Pressure < 65 mm Hg with use of pressor per ICU protocol
Irreversible condition (other than COVID-19) with projected fatal course
ECMO
Current or recent (within 30 d) enrollment in another investigational trial of anti-IL6 drug;
Active diagnosis of Acquired immune deficiency syndrome;
Transplant patients currently immunosuppressed;
Chemotherapy-induced neutropenia (granulocyte count <1000/mm3);
Cardiogenic shock; congestive heart failure - NYHA Class 3 or 4;
Recent myocardial infarction - within last 6 months and troponin > 0.5
Anuria (urine output < 50 ml/d) or other signs of multi-organ failure
Severe liver disease with portal hypertension;
Recent stroke or head trauma within last 12 months
Increased intracranial pressure, or other serious neurologic disorder;
Liquid Diarrhea more than 3x/day; defined as more than 3 non-bloody watery stools within a 24-hour period, requiring additional fluid and electrolyte supplementation








I haven’t see